IceCure Medical Ltd. ICCM 深 沪
交易中 03-26 11:18:06 美东时间
0.4201
-0.168
-28.55%
华盛通- 最 高0.4599
- 今 开0.43
- 成交量 186.41万股
- 最 低 0.41
- 昨 收 0.588
- 总市值 2897.14万
- 52周最高 1.40
- 市盈率 静 --
- 换手率 2.70%
- 52周最低 0.41
- 委 比 92.34%
- 总股本 6896.32万
- 历史最高 12.167
- 量 比 16.65
- 振 幅 8.49%
- 历史最低 0.41
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IceCure Reports 4-Year ICESECRET Results, With ProSense Showing Up To 89.4% Recurrence-Free Rates In Kidney Cancer Study
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study populationFull analysis of results to be presented at
03-25 20:39
IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm
IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients. At a median follow-
03-25 20:30
IceCure Appoints Meir Peleg As CFO, Effective May 17, 2026
Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director
03-24 20:37
IceCure names Meir Peleg CFO effective May 17, 2026
IceCure names Meir Peleg CFO effective May 17, 2026 IceCure appointed Meir Peleg as chief financial officer, effective May 17, 2026. Meir Peleg has over 20 years of financial leadership experience, including roles with Nasdaq-listed companies. The company said it intends to appoint Richard Fine as m
03-24 20:32
IceCure Appoints Meir Peleg as Chief Financial Officer
Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel...
03-24 20:30
电话会总结 ｜ IceCure Medical(ICCM)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据IceCure Medical业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩：**营收表现：** - 2025年全年营收达到340万美元，创历史新高 - 第四季度销售额约130万美元，同样创下季度纪录 - 营收增长主要由美国FDA批准ProSense用于低风险早期乳腺癌治疗以及在关键市场的持续增长和采用推动 **其他财务指标：** - 会议中提及详细财务结果已在当日早间发布的新闻稿中披露，但电话会议重点关注商业发展而非具体财务指标细节 - 未在会议中具体披露利润率、净利润、现金流等详细财务数据 ## 2. 财务指标变化：**同比变化：
03-18 12:29
Icecure Medical Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.279M Miss $1.900M Estimate
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 33.33 percent. This is a 25 percent increase over losses of $(0.08) per share from
03-17 20:32
IceCure FY 2025 net loss narrows 5% to USD 15.06 million
IceCure FY 2025 net loss narrows 5% to USD 15.06 million IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no
03-17 20:31
Earnings Scheduled For March 17, 2026
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is expected to ...
03-17 19:11
FDA approves IceCure’s ChoICE post-market ProSense cryoablation study in low-risk breast cancer
FDA approves IceCure’s ChoICE post-market ProSense cryoablation study in low-risk breast cancer IceCure said the FDA approved the design of its post-marketing ChoICE study evaluating ProSense cryoablation for local treatment of low-risk breast cancer. The study is expected to start enrolling patient
03-11 20:58
